Reference
Backes FJ, et al. Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?. International Journal of Gynecological Cancer 23: 833-838, No. 5, Jun 2013. Available from: URL: http://dx.doi.org/10.1097/IGC.0b013e318290ea69 - USA
Rights and permissions
About this article
Cite this article
Bevacizumab. Reactions Weekly 1468, 10 (2013). https://doi.org/10.1007/s40278-013-5620-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-013-5620-2